Janssen has announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib).
The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability.
These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA, US.
Ibrutinib, a first-in-class Bruton’s tyrosine kinase inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company.
MCL is one of several subtypes of B-cell non-Hodgkin lymphoma and represents about 5-7% of malignant lymphoma in Western Europe. MCL usually begins with lymph node enlargement and can potentially spread to other tissues such as the bone marrow and liver. Median overall survival for MCL patients is three to four years.
Dr Simon Rule, Professor in Haematology at Plymouth University Medical School, and lead investigator and presenter of the pooled analysis, said: “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma.
“Long-term follow-up for ibrutinib demonstrates, that in addition to efficacy, new onset adverse events decrease over time and are generally less common when patients are treated earlier.”
Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen Europe, Middle East and Africa, said: “As we build on the clinical evidence for ibrutinib, we continue to see sustained benefits in treating B-cell malignancies such as MCL, supporting positive outcomes for such a large patient population in the long-term.”